Insulet has secured an FDA clearance for its latest tubeless insulin pump, the Omnipod 5, a patch-like device capable of adjusting daily doses to changes in the wearer’s blood sugar levels. Designed ...

Insulet’s chief growth officer said: “colour has the power to differentiate a brand,” with mango orange adorning Omnipod’s ...

Insulet (Nasdaq:PODD) has its eyes on future expansion in new geographies, according to some of its leading executives.

Insulet Corp. received FDA clearance for its Omnipod 5 closed-loop automated insulin delivery (AID) system for patients aged six and older who have type 1 diabetes on Friday, Jan. 28, making it the ...

Two studies demonstrated that the Omnipod Horizon algorithm performed well in response to meal challenges and exercise in 24 adults with type 1 diabetes. Results showed strong blood glucose control ...

The FDA has cleared the first tubeless hybrid closed-loop insulin delivery system for people with type 1 diabetes aged 6 years and older, according to a press release from Insulet. The Omnipod 5 ...

Insulet Corporation PODD recently announced the commercial introduction of its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for people with type 1 diabetes (T1D) who are two years of age ...

Insulet Corp. once again broke records with a nearly 50% increase in Omnipod revenues in U.S. in the first quarter and a 32% increase in revenue from the tubeless insulin delivery device worldwide. In ...

Current work seeks to perfect the algorithm that would someday let the insulin pump automatically make the multitude of delivery decisions that would have been made by a healthy pancreas. Advances are ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...